open access

Vol 15, No 2 (2020)
Review Papers
Published online: 2020-04-01
Get Citation

Position paper of Scientific Committees of Polish Academy of Sciences (Committee on Therapy and Drug Research, Committee on Physiology and Pharmacology) and Polish scientific societies (Polish Society of Pharmacology, Polish Society of Clinical Pharmacology and Therapy, Polish Society of Arterial Hypertension, Working Group on Cardiovascular Pharmacotherapy of Polish Cardiac Society) on chloroquine in the treatment of COVID-19 patients infected with SARS-CoV-2

Dagmara Mirowska-Guzel, Tomasz Kocki, Bogusław Okopień, Włodzimierz Buczko, Filip M. Szymański, Krzysztof J. Filipiak
DOI: 10.5603/FC.a2020.0015
·
Folia Cardiologica 2020;15(2):114-117.

open access

Vol 15, No 2 (2020)
Review Papers
Published online: 2020-04-01

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Position paper of Scientific Committees of Polish Academy of Sciences (Committee on Therapy and Drug Research, Committee on Physiology and Pharmacology) and Polish scientific societies (Polish Society of Pharmacology, Polish Society of Clinical Pharmacology and Therapy, Polish Society of Arterial Hypertension, Working Group on Cardiovascular Pharmacotherapy of Polish Cardiac Society) on chloroquine in the treatment of COVID-19 patients infected with SARS-CoV-2

Journal

Folia Cardiologica

Issue

Vol 15, No 2 (2020)

Pages

114-117

Published online

2020-04-01

DOI

10.5603/FC.a2020.0015

Bibliographic record

Folia Cardiologica 2020;15(2):114-117.

Authors

Dagmara Mirowska-Guzel
Tomasz Kocki
Bogusław Okopień
Włodzimierz Buczko
Filip M. Szymański
Krzysztof J. Filipiak

References (15)
  1. Informacja w sprawie druków informacyjnych do produktu Arechin (Chloroquini phosphas), 250 mg, tabletki . http://www.urpl.gov.pl/pl/informacja-w-sprawie-druk%C3%B3w-informacyjnych-do-produktu-arechin-chloroquini-phosphas-250-mg-tabletki (March 30, 2020).
  2. Zhonghua Jie He He Hu Xi Za Zhi, Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia, 2020 Feb 20;43(0):E019. doi: 10 3760/cma j issn 1001-0939. 2020; 0019(streszczenie).
  3. Cortegiani A, Ingoglia G, Ippolito M, et al. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 [Epub ahead of print].
  4. Racagni G., Cirino G., Mugelli A. i wsp., Do effective drugs against COVID-19 (already in use or under clinical development) exist? (list Zarządu Włoskiego Towarzystwa Farmakologicznego do członków Europejskiej Federacji Towarzystw Farmakologicznych). http://oilbialystok.pl/informacja-dotyczaca-chlorochiny-w-leczeniu-zakazenia-wirusem-sars-cov-2-powodujacego-covid-19/ (March, 20, 2020).
  5. Aralen® Chloroquine phosphate, USP. For Malaria and Extraintestinal Amebiasis. FDA, 1949. https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/06002slr039_aralen_lbl.pdf (March 30, 2020).
  6. Charakterystyka Produktu Leczniczego. http://www.urpl.gov.pl/sites/default/files/Arechin%20Charakterystyka%20Produktu%20Leczniczego.pdf (March 30, 2020).
  7. Ulotka dołączona do opakowania: informacja dla pacjenta . http://www.urpl.gov.pl/sites/default/files/Arechin%20Ulotka%20dla%20Pacjenta.pdf (March 30, 2020).
  8. Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 [Epub ahead of print]: 105938.
  9. Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003; 3(11): 722–727.
  10. Shen H, Wu Na, Wang Yu, et al. Chloroquine attenuates paraquat-induced lung injury in mice by altering inflammation, oxidative stress and fibrosis. Int Immunopharmacol. 2017; 46: 16–22.
  11. Balasubramanyan N, Murphy A, O'Sullivan J, et al. Familial interstitial lung disease in children: response to chloroquine treatment in one sibling with desquamative interstitial pneumonitis. Pediatr Pulmonol. 1997; 23(1): 55–61.
  12. Klinger G, Morad Y, Westall C, et al. Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. The Lancet. 2001; 358(9284): 813–814.
  13. Götestam Skorpen C, Hoeltzenbein M, Tincani A, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016; 75(5): 795–810.
  14. Patro-Małysza J, Marciniak B, Kimber-Trojar Ż, et al. Farmakoterapia chorób układu ruchu u kobiet w ciąży. Ginekol Perinatol Prakt. 2016; 1(2): 56–65.
  15. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 [Epub ahead of print]: 105949.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl